Pneumococcal conjugate vaccine

As facilities use the lessons learned to put in place policies and programs to continue delivering COVID-19 vaccines, they also should evaluate the quality and effectiveness of their influenza and pneumococcal immunization programs.

A pneumonia vaccine previously recommended only for infants and young children, has now been approved for adults ages 50 and older, the Food and Drug Administration announced.